

Basingstoke, Southampton and Winchester District Prescribing Committee (DPC)

Recommendations of the meeting of 16 April 2013

Supported or limited support, e.g. specialist recommendation/initiation

- **Linagliptin** – The Committee supported the availability locally of this ‘gliptin’. For patients with renal impairment no dose adjustment is required.
- **Lixisenatide** – The Committee supported the availability of this once daily injectable GLP-1 mimetic. It is less expensive than exenatide (twice daily and once weekly) and liraglutide (once daily). The Committee recommended that prescribers give consideration to using lixisenatide as first choice GLP-1 mimetic in new patients.
- **Insulin Degludec** – The Committee supported the use of this ultra long insulin analogue in patients with problematic type 1 diabetes. The insulin should be initiated and stabilised by a specialist and is therefore classified as ‘Amber’.
- **Mirabegron for the treatment of over active bladder** – The Committee supported the availability of this new agent in line with the draft NICE guidance; Mirabegron is recommended as an option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects. Until final guidance from NICE is available the Committee recommended that mirabegron should be specialist initiated or recommended (i.e. ‘Amber’) and the specialist should advise the patient and GP of the side effect profile of this new agent.
- **Apixaban** – NICE has supported this third newer oral anticoagulant as an option in the prevention of stroke in people with AF (alongside warfarin, dabigatran and rivaroxaban). The local decision aid is currently being updated so as to include apixaban.

Not Supported currently

- **Dapagliflozin for the treatment of type 2 diabetes** – pending final NICE guidance the Committee does not support the routine use of this new agent; however the Committee acknowledged that it may have a place in a small number of patients. Such treatment should be initiated or recommended by a specialist and provide the patient and GP with details of possible side effects and cautions.
- **SportVis (sodium hyaluronate injection)** – The Committee did not support the use of this peri articular injection locally.

Information / Reminders / Updates/ Safety Messages / NICE

- **Updated osteoporosis guidelines and denosumab shared care guidelines** were approved by the Committee. The Committee recommended that denosumab should remain as ‘Amber’.
- **Naltrexone oral tablets for maintaining alcohol abstinence shared care guidelines** were approved by the Committee.
- **Updated Wound Formulary** -The updated Wound Formulary is currently being distributed to practice nurses, community nurses and nursing homes.